Last mentioned: Mar 21, 2026
Motion to Dismiss Phase
Defendants expected to file motions to dismiss based on Safe Harbor protections for forward-looking statements.
Discovery Phase Begins
Courts likely to rule on motions to dismiss, leading to the exchange of internal corporate documents.
Lead Plaintiff Deadline
Estimated deadline for investors to file motions to be appointed as lead plaintiff in the respective cases.
Lead Plaintiff Deadline (Est.)
Typical 60-day window for investors to petition the court to lead the consolidated class action.
Lead Plaintiff Deadline (Estimated)
Expected window for investors to file motions to lead the class actions against RARE, MREO, and NAVAN.
Investigation Announcement
Pomerantz Law Firm publicly announces investigations into both EHC and VSCO on behalf of investors.
Investigation Announced
Pomerantz Law Firm issues a formal investor alert regarding potential claims against Encompass Health Corporation.
Concurrent Probe
Pomerantz announces a similar investigation into Victoria's Secret & Co. (VSCO).
EHC Material Agreement
Encompass Health Corp files notice of a material definitive agreement and new financial obligations.
Market Reaction
Investors and analysts begin assessing the potential litigation overhang on RARE, MREO, FRMI, and NAVN.
Investor Alerts Issued
Pomerantz Law Firm releases simultaneous reminders for class action lawsuits against four companies.
Investor Alerts Issued
Pomerantz Law Firm releases multiple reminders for class action deadlines across the biotech sector.
Coordinated Legal Alerts
Pomerantz Law Firm issues a series of reminders for class action deadlines across four major firms.
VSCO Financial Disclosure
Victoria's Secret & Co. files 8-K regarding results of operations and financial condition.
Market Monitoring
Legal firms monitor EHC's post-spin-off financial performance and regulatory compliance for potential disclosure gaps.
Pomerantz LLP has filed a class action lawsuit against Gemini Space Station, Inc. (GEMI) and its executive officers, alleging violations of federal securities laws. The litigation seeks to recover damages for investors who purchased GEMI securities during the specified class period.
Pomerantz Law Firm has initiated dual investigations into Encompass Health Corporation and Victoria's Secret & Co. regarding potential securities fraud and unlawful business practices. These probes signal rising litigation risk for the healthcare and retail sectors as investors scrutinize corporate disclosures and guidance accuracy.
Pomerantz Law Firm has initiated an investigation into Encompass Health Corporation (EHC) regarding potential securities fraud and unlawful business practices. The probe seeks to determine if the company or its officers misled investors, following a period of significant corporate restructuring and market volatility.
Pomerantz Law Firm has initiated formal investigations into Encompass Health Corporation and Victoria’s Secret & Co. regarding potential securities fraud and breaches of fiduciary duty. The probes follow recent material financial disclosures and SEC filings that have triggered concerns over the accuracy of corporate communications to investors.
Pomerantz Law Firm has issued urgent reminders for investors regarding class action lawsuits against Trip.com Group, Aquestive Therapeutics, and Driven Brands Holdings. These legal actions focus on alleged securities violations and material misrepresentations that resulted in significant shareholder losses.
Pomerantz Law Firm has issued a formal reminder to Aquestive Therapeutics (AQST) investors regarding an ongoing class action lawsuit following a period of financial underperformance. The litigation coincides with a recent quarterly earnings miss and notable insider selling, creating a challenging regulatory and legal environment for the biotech firm.
Pomerantz Law Firm has issued urgent reminders to investors regarding upcoming lead plaintiff deadlines in class action lawsuits against Trip.com Group Limited, Driven Brands Holdings Inc., and Aquestive Therapeutics, Inc. These legal actions allege violations of federal securities laws, primarily focusing on misleading statements or omissions that resulted in significant financial losses for shareholders.
Pomerantz Law Firm has issued urgent reminders for investors regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These legal actions target alleged securities fraud and disclosure failures, setting critical deadlines for lead plaintiff applications.
Pomerantz Law Firm has issued urgent reminders to investors regarding class action deadlines for Ultragenyx, Mereo BioPharma, Navan, and Fermi. These legal actions follow allegations of misleading statements and failures to disclose material risks concerning clinical data and financial projections.
Pomerantz Law Firm has issued a series of investor alerts regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These filings highlight a surge in securities litigation targeting volatility in the biotechnology and emerging technology sectors, emphasizing critical lead plaintiff deadlines for affected shareholders.
Pomerantz Law Firm has initiated a series of investigations into seven companies, including Snowflake and Navan, regarding potential securities fraud and unlawful business practices. These probes target firms across the technology, finance, and healthcare sectors, signaling a heightened period of legal scrutiny for public entities.